Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Neoleukin Therapeutics, Inc. NLTX NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Neoleukin Therapeutics, Inc. (NLTX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.49. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $90M (loss), growing at -15.2%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $10M against $265M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 16.56 (strong liquidity). Debt-to-assets is 3.4%. Total assets: $289M.

Analyst outlook: 5 / 14 analysts rate NLTX as buy (36%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 20/100 (Fail), Income ?/100 (Fail).

NLTX SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NLTX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
NLTX: -100%/yr revenue is, -15.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet NLTX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 16.56 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
NLTX: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 5 / 14 analysts rate NLTX as buy (36%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.42-18.8
Volume109.1K
Avg Volume (30D)5.52K
Market Cap$8.2M
Beta (1Y)1.10
Share Statistics
IPO Date2014-03-07
Employees7
CEODonna M. Cochener-Metcalfe
Financial Highlights & Ratios
EBITDA$-103.33M
Net Income$-90.35M
Operating Income$-103.33M
Total Cash$269.01M
Total Debt$9.89M
Net Debt$-93.95M
Total Assets$288.6M
Analyst Forecast
Rating ConsensusHold
Analysts Covering14
Buy 36% Hold 57% Sell 7%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS64049K2033

Price Chart

Track all markets on TradingView
NLTX
Neoleukin Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Drug Manufacturers - Specialty & Generic
3.42 52WK RANGE 18.80

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.56
+0.44%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.81
+1.26%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.64
-5.04%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.89
+5.33%
 NXTC
NXTC
NextCure, Inc.
$12.02
-5.87%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message